Regeneron Pharmaceuticals has entered into a strategic licensing agreement with China’s Hansoh Pharmaceutical to advance its next-generation obesity and metabolic therapies. Through the deal, valued at up to US$2.01 B, Regeneron gains exclusive global rights (excluding Greater China) to HS-20094, a dual GLP-1/GIP receptor agonist in late-stage clinical development for obesity and diabetes. This enables Regeneron to integrate HS-20094 with its proprietary programmes aimed at improving quality of weight loss and preserving lean mass. The partnership is aimed to boost Regeneron’s position in the metabolic space against players like Eli Lilly’s Zepbound (tirzepatide).